Medicare Part B Payment Redux

by King & Spalding
Contact

Another Presidential Administration Attempts to Change Part B Payment for Physician-Administered Drugs

On October 25, 2018, the Trump Administration released an Advance Notice of Proposed Rulemaking (“ANPRM”) entitled “International Pricing Index Model for Medicare Part B Drugs,” soliciting comments on a proposal to reset Medicare Part B drug payment rates to more closely align with international “prices” for the drugs paid by other countries.[i]  Comments on the proposal are due by December 31, 2018.

The proposal, which would be implemented as a demonstration project through the Center for Medicare and Medicaid Innovation (“CMMI”), would operate for five years, during which time certain Part B drug payment rates to both physicians and hospital outpatient departments would be lowered to some proportion of a product’s “Average Sales Price” and its newly created “Target Price” based on its “International Pricing Index” value.  In doing so, the Administration aims to further two of its policy goals—(1) the Medicare program should not be faced with higher drug prices compared to drug prices in other countries where national health systems directly negotiate prices with drug manufacturers; and (2) the United States government should not directly negotiate Part B drug prices with manufacturers.  In addition, the proposal seeks to modify the statutory +6% “add-on payment” that allegedly creates incentives for providers to prescribe more expensive drugs, and to reduce physician financial burden inherent in a “buy and bill” system by enabling private sector vendors to purchase and distribute Part B drugs. 

Importantly, the Administration’s announcement is only an “Advance Notice” seeking public comments on the proposed concept—the Centers for Medicare & Medicaid Services (“CMS”) must still issue a Proposed Rule outlining the precise parameters of the demonstration project for further comment prior to issuance of a Final Rule and launch of the model.  Although CMS anticipates issuing a Proposed Rule in Spring 2019 and running the model between 2020 and 2025, it may be many months, if not years, before a Proposed Rule is issued and the changes described in the ANPRM are effectuated.  Moreover, the issuance of this ANPRM just a few days before the 2018 mid-term elections has led to speculation that the Administration may have timed the proposal for political reasons.  Either way, the proposal raises issues that are of significant interest to stakeholders involved with access to physician-administered drugs (in both the Medicare and Medicaid programs), including manufacturers, physicians, hospitals, patient groups, State Medicaid programs, and entities that may be interested in becoming private sector vendors under the proposed model.

Background

Prior to 2005, the Medicare payment amount for Part B drugs and biologicals was based on 95% of a published price known as “Average Wholesale Price” or AWP (which is still published today by certain commercial drug price compendia).  Due to concern that AWP was not an actual market price, in 2003, Congress changed the basis for payment to “Average Sales Price,” or ASP—generally, the actual volume weighted average sales price that manufacturers charge to commercial purchasers and payers.[ii]  Effective January 1, 2005, drugs and biologicals not paid on a cost or prospective payment basis were paid based on the ASP methodology, with payment to providers at a statutory rate of ASP+6% (or 106% of the ASP) for each drug or biological.  The ASP methodology uses quarterly drug pricing data submitted to CMS by drug manufacturers.  There is a two-quarter lag between the sales period for which ASPs are reported and the effective date of the payment amounts (for example, sales and discounting data from the first quarter of 2018 were used to establish payment amounts for the third quarter of 2018). 

There are two important features of the current system relevant to the ANPRM—first, and contrary to many of the statements made by the Administration, ASP is a true market price for drugs and biologicals, as it is calculated using actual sales prices net of discounts, rebates and chargebacks.  Second, CMS makes Medicare Part B payments for drugs and biologicals to providers—physicians and hospitals—who themselves have to purchase the drugs on the open market.  To account for the fact that providers have overhead costs related to purchasing these drugs, and may not be able to purchase them at or below ASP, Congress directed that payment be set at ASP+6%. 

Unfortunately, many policymakers misunderstand the purpose of the “+6%” add-on payment, wrongly believing it to be purely incentive to providers to use more expensive drugs.  To remove that incentive, in March 2016, the Obama Administration proposed a demonstration project using CMMI authority that would have converted the percentage add-on payment to “+2.5%” and an additional fixed dollar amount.[iii]  The proposal resulted in such a firestorm of criticism from Republicans in Congress, providers and patient groups, that the Obama Administration withdrew the proposal in October 2017.[iv]

In addition to concerns about ASP-based payment, the Trump Administration has also criticized the fact that Medicare Part B drugs are less expensive in foreign countries, where national health systems directly negotiate pricing with manufacturers.  This disparity has long existed, but CMS has not previously focused on this issue, which is complicated by the general aversion to having the United States government directly negotiate with drug manufacturers over prices.  Thus, until the ANPRM, CMS has not offered any suggestions for ways to align Medicare Part B payments with the lower amounts that foreign governments pay for the same drugs and biologicals. 

The ANPRM Proposal

To tie these issues together, the ANPRM proposes a demonstration project that would modify Medicare Part B payment rates, including add-on payment rates, as well as the structure of the “buy and bill” purchasing framework, in certain geographic areas of the country (yet to be determined, although the total areas would encompass 50% of Medicare Part B spending on separately payable Part B drugs).  Within these geographic areas, all physician practices and hospital outpatient departments (and potentially other categories of providers and suppliers) would be required to participate in the demonstration project for certain Medicare Part B drugs and biologicals.

Which drugs and biologicals will be part of the demonstration project?

The ANPRM proposes to initially include in the demonstration project single source drugs, biologicals (including biosimilars), and multiple source drugs with a single manufacturer that are administered “incident to a physician’s services” for which there are reliable sources of international pricing data.  In the hospital outpatient setting, separately payable drugs and biologicals, including those on pass-through payment status, would be included.  Excluded from the demonstration project are: (1) drugs identified by the FDA to be in short supply; (2) drugs paid under “miscellaneous” or “not otherwise classified” codes, including compounded drugs; (3) radiopharmaceuticals; (4) End Stage Renal Disease (“ESRD”) drugs; and (5) drugs that are packaged in Medicare’s Hospital Outpatient Prospective Payment System (“the OPPS”).

How will the new Medicare Part B payment rate be calculated? 

The five-year demonstration project would set Medicare Part B payment rates for drugs and biologicals based on a descending blend of ASP and a “Target Price” based on a new International Pricing Index (“IPI”) figure.  Specifically, in the first year of the demonstration, the payment amount would be determined using 80% ASP and 20% Target Price, in Year Two it would be 60% ASP and 40% Target Price, in Year Three the payment amount would be 40% ASP and 60% Target Price, in Year Four it would be 20% ASP and 80% Target Price, and in Year Five it would be 100% Target Price.

The Target Price for a particular drug or biological is derived from the IPI, which is based on the ratio of Medicare spending for the product using ASP prices to the estimated spending for the product using international prices.  The international prices are proposed to be based upon drug prices in countries that have economies comparable to the United States or countries that are included in Germany’s market basket for reference pricing for their drug prices:  Austria, Belgium, Canada, Czech Republic, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Japan, Netherlands and the United Kingdom.  Indeed, hours before the ANPRM was announced, the HHS Office of the Assistant Secretary for Planning and Evaluation (“ASPE”) issued an extensive report documenting the payments in many of these countries for the top 50 most expensive drugs in the Medicare Part B program.[v]  CMS is considering whether to rely on existing data sources for international prices or implement a manufacturer data collection and reporting system—similar to the ASP reporting system—whereby manufacturers report to CMS international sales data for prices and units of product sold.  CMS anticipates that payment amounts in the demonstration would be updated on a quarterly basis.

Administration officials have broadly suggested that this tie to international drug prices will cause manufacturers to “adjust their global pricing strateg[ies],”[vi] presumably raising their foreign prices to avoid a reduction in domestic Medicare reimbursement.  How this result would reduce domestic drug prices is unclear.

How will the “buy and bill” system be modified? 

The ANPRM also addresses a fundamental structural difference between European countries that negotiate drug prices directly, and the Medicare system of reimbursement to providers who purchase Part B drugs.  The Trump Administration acknowledges that foreign governments can negotiate drug prices with manufacturers because they are able to leverage the volume of patients in the country in their negotiations.  The Medicare system has no such leverage—all CMS can do is announce that it will reimburse providers at a lower rate, and hope that manufacturers will lower drug prices in response to pressure from providers.  To create market leverage in the Medicare Part B program, the ANPRM proposes to select through a competitive process a group of at least three national “vendors” who would negotiate with manufacturers to reduce drug prices on behalf of providers who enroll with those vendors.  The providers would pay the vendors for distribution services, and the vendors would bill and receive payment from the Medicare program for drug and biological products administered by the enrolled providers.  The vendors, not providers, would purchase and take title of drug products, but the vendors would not be required to take physical possession of those products.  Providers would collect beneficiary deductible and coinsurance amounts, and would bill supplemental insurers.  The ANPRM does not suggest that vendors would have any authority to impose formulary restrictions, potentially undermining their ability to demand and obtain price concessions from manufacturers.

It is likely that pharmacy benefit managers (“PBMs”) will be best situated to become vendors in the demonstration project given that they already have experience negotiating drug prices with manufacturers and know how to aggregate entities to create market leverage.  The ANPRM suggests that other entities may also qualify, including wholesalers, distributors, group purchasing organizations, specialty pharmacies, individual or groups of physicians or hospitals, and Medicare Part D sponsors.  This is a change from the Competitive Acquisition Program (“CAP”) that was briefly in effect during the 2000s, in which only specialty pharmacies could qualify as vendors.  Providers would be encouraged to enroll with at least one, but preferably, multiple vendors in order to obtain drugs from the vendor offering the most cost-effective arrangement.

We note that sales to these vendors would not be excluded from Medicaid Best Price calculations.  Exempting such sales would be one way to further the success of the demonstration project, however, such an exemption would need to be made by statutory change. 

What changes to the add-on payment are proposed?

The ANPRM also proposes that physicians and hospitals participating in the demonstration project would be paid a set payment amount per encounter or per month for a drug rather than a percentage add-on payment (+6%) per drug product, which CMS believes creates incentives to administer more costly drug products.  The set payment could be based on a class of drugs, a physician specialty, or a particular physician practice or hospital.  The set payment amount would be calculated annually based on the +6% of ASP revenue that the demonstration participants would have garnered without sequestration in the most recent year of claims data.  CMS is also considering whether to create a “bonus pool” through which physicians can achieve bonus payments for prescribing lower-cost drugs or practicing evidence-based utilization.

Estimated Cost Savings from the Proposal 

The Trump Administration estimates that the proposal to modify the Medicare Part B drug payment rate, if implemented, would result in $12.5 billion in savings over the five years of the demonstration project, with an additional $9.2 billion of savings through the Medicare Advantage program (totaling $21.7 billion of savings).  Taking into account an expected $4.8 billion in physician add-on payments, the overall net savings for the Medicare program is estimated to be $16.3 billion.  In addition, there are also some highly speculative expected Medicaid savings (due to a lower Best Price which would increase the Medicaid rebate for some products, although reduced Average Manufacturer Price may offset this) of approximately $1.6 billion.  These figures assume no changes in utilization, although we expect that involvement of the vendors almost certainly guarantees that utilization would change.  In addition, Medicare beneficiaries who do not have supplemental coverage and would otherwise be responsible for a 20% coinsurance for Part B drugs would also save funds as a result of the proposed demonstration project.

The Administration’s Authority for this Demonstration 

Because the ASP-based payment methodology was created by Congress and codified into law since 2003, many have questioned whether the demonstration project can be implemented without statutory change.  The Administration’s position is that it possesses authority through the CMMI to create and operate the demonstration.  Section 1115A of the Social Security Act permits Medicare to enact demonstration programs to test payment models that would reduce costs without harming care.  This authority contains a broad waiver of any provision of the Medicare statute (Title XVIII of the Social Security Act), including the ASP payment methodology and OPPS provisions.  The CMMI authority also permits waiver of specific provisions of the Medicaid statute—not including the Medicaid Best Price requirements—which means that lower Medicare Part B payment rates may result in lower Medicaid Best Price figures for certain products, which would yield the Medicaid savings noted above. 

The very same Section 1115A authority was relied upon by the Obama Administration for its proposed Part B demonstration, however, many accused the Obama Administration of not meeting certain key requirements of the statute, including that a demonstration project must not be national in scope and must be limited in both geography and time.  The statute also requires that the demonstration program save funds while not reducing quality of care; the Obama Administration demonstration was intended only to be budget neutral.  While the Trump Administration appears to have been more careful in its adherence to the Section 1115A requirements, these conditions have never been tested in a court and it is unclear how they would be construed.  Notwithstanding the judicial review limitations in Section 1115A, if the Trump Administration proceeds with the demonstration, we should expect a legal challenge to the program as exceeding CMS’s lawful authority, potentially buttressed by constitutional challenges to the statute itself, which purports to delegate substantial authority to CMS to waive statutory requirements and exercise what would appear to be legislative power.

Stakeholder Reaction 

As noted above, the Obama Administration proposal, which was more modest in scope, drew extensive opposition from physicians, hospitals, drug manufacturers, and patient advocates.  The Trump Administration proposal will be sure to draw no less ire, and we anticipate an even more heated debate in Congress and in the media over the proposal.  Although groups like the American Medical Association have issued cautious statements,[vii] others like PhRMA were swift and strong in their objections to the proposal.[viii]  If history is any guide, opposition is expected to mount in the coming weeks and months as providers and patients internalize the change to payment rates and to access that could be impacted by the proposal.

Curiously, the Trump Administration’s own words may be used against the proposal.  In May 2018, the Administration published its drug pricing “Blueprint” in which it addressed in detail the international pricing scheme, but noted that using “the price of a medicine in one or several countries to derive a benchmark or reference price” would effectively be implementing “price controls [that] prevent drug companies from charging market rates for their products, while delaying the availability of new cures to patients living in countries implementing these policies.”[ix]

Manufacturers may already be thinking about options to avoid lower Medicare Part B payment amounts.  One simple idea would be to shift Part B products into the Part D program by creating self-administration delivery mechanisms such as auto-injectors.  (It is important to know that the Trump Administration is intending to publish a Part D Drug Pricing proposed rule in the next few weeks, which may address this issue.)  In another approach, manufacturers could license core intellectual property to European subsidiaries who could create “new” drugs with minor differences that could be “approved” in foreign countries, but that would be distinct drugs from those used in the United States such that they would not be used to calculate an IPI value.  European countries would likely have an interest in facilitating the approvals of these “new” drugs for use in countries measured for the IPI value, given that manufacturers otherwise may increase drug prices in these countries in order to maintain higher Medicare payment rates in the United States.

Next Steps

The ANPRM was published in the Federal Register on October 30, 2018, and interested stakeholders are invited to submit comments by December 31, 2018.  Following submission of the comments, it will likely take the Trump Administration several months to analyze the comments and issue a formal Proposed Rule, following which another round of comments would be submitted.  Undoubtedly, we expect an intense internal debate within the Trump Administration over the proposal, and whether and how to implement it.  Moreover, even if the demonstration program is finalized, it is unclear whether any vendors will seek to participate in the program, and if vendors that do participate will be able to negotiate drug prices that are low enough to offer to providers in their networks.

[i] See Centers for Medicare & Medicaid Services, Advanced Notice of Proposed Rulemaking with Comment, “Medicare Program; International Pricing Index Model for Medicare Part B Drugs,” 83 Fed. Reg. 54,546 (October 30, 2018), available at https://www.gpo.gov/fdsys/pkg/FR-2018-10-30/pdf/2018-23688.pdf.

[ii] Section 303(c) of the Medicare Modernization Act of 2003 (“MMA”) amended Title XVIII of the Act by adding section 1847A, which established a new ASP drug payment system.  See 42 U.S.C. § 1395w-3a; 42 C.F.R. § 414.800, et seq.

[iii] See Centers for Medicare & Medicaid Services, Proposed Rule, “Medicare Program; Part B Drug

Payment Model,” 81 Fed. Reg. 13,230 (March 11, 2016), available at https://www.gpo.gov/fdsys/pkg/FR-2016-03-11/pdf/2016-05459.pdf.   

[iv] See Centers for Medicare & Medicaid Services, Withdrawal of Proposed Rule, “Medicare Program; Part B Drug

Payment Model; Withdrawal,” 81 Fed. Reg. 46,182 (October 4, 2017), available at https://www.gpo.gov/fdsys/pkg/FR-2017-10-04/pdf/2017-21420.pdf.

[v] U.S. Department of Health and Human Services, Office of the Assistant Secretary for Planning and Evaluation, Report, “Comparison of U.S. and International Prices for Top Medicare Part B Drugs by Total Expenditures” (October 25, 2018), available at  https://aspe.hhs.gov/system/files/pdf/259996/ComparisonUSInternationalPricesTopSpendingPartBDrugs.pdf.     

[vi] See Dan Best (Senior Advisor to the Secretary for Drug Price Reform), HHS.gov Blog Post, “Answering Your Questions About the IPI Drug Pricing Model” (October 30, 2018), at https://www.hhs.gov/blog/2018/10/30/answering-your-questions-about-the-ipi-drug-pricing-model.html

[vii] American Medical Association, “Statement on President’s Plan for Prescription Drugs” (October 25, 2018), at https://www.ama-assn.org/ama-statement-president-s-plan-prescription-drugs.

[viii] Pharmaceutical Research and Manufacturers of America, Press Release, “Statement on HHS Speech and Part B Proposal” (October 25, 2018), at https://www.phrma.org/press-release/phrma-statement-on-hhs-speech-and-part-b-proposal.   

[ix] “American Patients First:  The Trump Administration Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs” (May 2018) at 15, available at https://www.hhs.gov/sites/default/files/AmericanPatientsFirst.pdf.

 

Written by:

King & Spalding
Contact
more
less

King & Spalding on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide

JD Supra Privacy Policy

Updated: May 25, 2018:

JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.

This Privacy Policy describes how JD Supra, LLC ("JD Supra" or "we," "us," or "our") collects, uses and shares personal data collected from visitors to our website (located at www.jdsupra.com) (our "Website") who view only publicly-available content as well as subscribers to our services (such as our email digests or author tools)(our "Services"). By using our Website and registering for one of our Services, you are agreeing to the terms of this Privacy Policy.

Please note that if you subscribe to one of our Services, you can make choices about how we collect, use and share your information through our Privacy Center under the "My Account" dashboard (available if you are logged into your JD Supra account).

Collection of Information

Registration Information. When you register with JD Supra for our Website and Services, either as an author or as a subscriber, you will be asked to provide identifying information to create your JD Supra account ("Registration Data"), such as your:

  • Email
  • First Name
  • Last Name
  • Company Name
  • Company Industry
  • Title
  • Country

Other Information: We also collect other information you may voluntarily provide. This may include content you provide for publication. We may also receive your communications with others through our Website and Services (such as contacting an author through our Website) or communications directly with us (such as through email, feedback or other forms or social media). If you are a subscribed user, we will also collect your user preferences, such as the types of articles you would like to read.

Information from third parties (such as, from your employer or LinkedIn): We may also receive information about you from third party sources. For example, your employer may provide your information to us, such as in connection with an article submitted by your employer for publication. If you choose to use LinkedIn to subscribe to our Website and Services, we also collect information related to your LinkedIn account and profile.

Your interactions with our Website and Services: As is true of most websites, we gather certain information automatically. This information includes IP addresses, browser type, Internet service provider (ISP), referring/exit pages, operating system, date/time stamp and clickstream data. We use this information to analyze trends, to administer the Website and our Services, to improve the content and performance of our Website and Services, and to track users' movements around the site. We may also link this automatically-collected data to personal information, for example, to inform authors about who has read their articles. Some of this data is collected through information sent by your web browser. We also use cookies and other tracking technologies to collect this information. To learn more about cookies and other tracking technologies that JD Supra may use on our Website and Services please see our "Cookies Guide" page.

How do we use this information?

We use the information and data we collect principally in order to provide our Website and Services. More specifically, we may use your personal information to:

  • Operate our Website and Services and publish content;
  • Distribute content to you in accordance with your preferences as well as to provide other notifications to you (for example, updates about our policies and terms);
  • Measure readership and usage of the Website and Services;
  • Communicate with you regarding your questions and requests;
  • Authenticate users and to provide for the safety and security of our Website and Services;
  • Conduct research and similar activities to improve our Website and Services; and
  • Comply with our legal and regulatory responsibilities and to enforce our rights.

How is your information shared?

  • Content and other public information (such as an author profile) is shared on our Website and Services, including via email digests and social media feeds, and is accessible to the general public.
  • If you choose to use our Website and Services to communicate directly with a company or individual, such communication may be shared accordingly.
  • Readership information is provided to publishing law firms and authors of content to give them insight into their readership and to help them to improve their content.
  • Our Website may offer you the opportunity to share information through our Website, such as through Facebook's "Like" or Twitter's "Tweet" button. We offer this functionality to help generate interest in our Website and content and to permit you to recommend content to your contacts. You should be aware that sharing through such functionality may result in information being collected by the applicable social media network and possibly being made publicly available (for example, through a search engine). Any such information collection would be subject to such third party social media network's privacy policy.
  • Your information may also be shared to parties who support our business, such as professional advisors as well as web-hosting providers, analytics providers and other information technology providers.
  • Any court, governmental authority, law enforcement agency or other third party where we believe disclosure is necessary to comply with a legal or regulatory obligation, or otherwise to protect our rights, the rights of any third party or individuals' personal safety, or to detect, prevent, or otherwise address fraud, security or safety issues.
  • To our affiliated entities and in connection with the sale, assignment or other transfer of our company or our business.

How We Protect Your Information

JD Supra takes reasonable and appropriate precautions to insure that user information is protected from loss, misuse and unauthorized access, disclosure, alteration and destruction. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. You should keep in mind that no Internet transmission is ever 100% secure or error-free. Where you use log-in credentials (usernames, passwords) on our Website, please remember that it is your responsibility to safeguard them. If you believe that your log-in credentials have been compromised, please contact us at privacy@jdsupra.com.

Children's Information

Our Website and Services are not directed at children under the age of 16 and we do not knowingly collect personal information from children under the age of 16 through our Website and/or Services. If you have reason to believe that a child under the age of 16 has provided personal information to us, please contact us, and we will endeavor to delete that information from our databases.

Links to Other Websites

Our Website and Services may contain links to other websites. The operators of such other websites may collect information about you, including through cookies or other technologies. If you are using our Website or Services and click a link to another site, you will leave our Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We are not responsible for the data collection and use practices of such other sites. This Policy applies solely to the information collected in connection with your use of our Website and Services and does not apply to any practices conducted offline or in connection with any other websites.

Information for EU and Swiss Residents

JD Supra's principal place of business is in the United States. By subscribing to our website, you expressly consent to your information being processed in the United States.

  • Our Legal Basis for Processing: Generally, we rely on our legitimate interests in order to process your personal information. For example, we rely on this legal ground if we use your personal information to manage your Registration Data and administer our relationship with you; to deliver our Website and Services; understand and improve our Website and Services; report reader analytics to our authors; to personalize your experience on our Website and Services; and where necessary to protect or defend our or another's rights or property, or to detect, prevent, or otherwise address fraud, security, safety or privacy issues. Please see Article 6(1)(f) of the E.U. General Data Protection Regulation ("GDPR") In addition, there may be other situations where other grounds for processing may exist, such as where processing is a result of legal requirements (GDPR Article 6(1)(c)) or for reasons of public interest (GDPR Article 6(1)(e)). Please see the "Your Rights" section of this Privacy Policy immediately below for more information about how you may request that we limit or refrain from processing your personal information.
  • Your Rights
    • Right of Access/Portability: You can ask to review details about the information we hold about you and how that information has been used and disclosed. Note that we may request to verify your identification before fulfilling your request. You can also request that your personal information is provided to you in a commonly used electronic format so that you can share it with other organizations.
    • Right to Correct Information: You may ask that we make corrections to any information we hold, if you believe such correction to be necessary.
    • Right to Restrict Our Processing or Erasure of Information: You also have the right in certain circumstances to ask us to restrict processing of your personal information or to erase your personal information. Where you have consented to our use of your personal information, you can withdraw your consent at any time.

You can make a request to exercise any of these rights by emailing us at privacy@jdsupra.com or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

You can also manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard.

We will make all practical efforts to respect your wishes. There may be times, however, where we are not able to fulfill your request, for example, if applicable law prohibits our compliance. Please note that JD Supra does not use "automatic decision making" or "profiling" as those terms are defined in the GDPR.

  • Timeframe for retaining your personal information: We will retain your personal information in a form that identifies you only for as long as it serves the purpose(s) for which it was initially collected as stated in this Privacy Policy, or subsequently authorized. We may continue processing your personal information for longer periods, but only for the time and to the extent such processing reasonably serves the purposes of archiving in the public interest, journalism, literature and art, scientific or historical research and statistical analysis, and subject to the protection of this Privacy Policy. For example, if you are an author, your personal information may continue to be published in connection with your article indefinitely. When we have no ongoing legitimate business need to process your personal information, we will either delete or anonymize it, or, if this is not possible (for example, because your personal information has been stored in backup archives), then we will securely store your personal information and isolate it from any further processing until deletion is possible.
  • Onward Transfer to Third Parties: As noted in the "How We Share Your Data" Section above, JD Supra may share your information with third parties. When JD Supra discloses your personal information to third parties, we have ensured that such third parties have either certified under the EU-U.S. or Swiss Privacy Shield Framework and will process all personal data received from EU member states/Switzerland in reliance on the applicable Privacy Shield Framework or that they have been subjected to strict contractual provisions in their contract with us to guarantee an adequate level of data protection for your data.

California Privacy Rights

Pursuant to Section 1798.83 of the California Civil Code, our customers who are California residents have the right to request certain information regarding our disclosure of personal information to third parties for their direct marketing purposes.

You can make a request for this information by emailing us at privacy@jdsupra.com or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

Some browsers have incorporated a Do Not Track (DNT) feature. These features, when turned on, send a signal that you prefer that the website you are visiting not collect and use data regarding your online searching and browsing activities. As there is not yet a common understanding on how to interpret the DNT signal, we currently do not respond to DNT signals on our site.

Access/Correct/Update/Delete Personal Information

For non-EU/Swiss residents, if you would like to know what personal information we have about you, you can send an e-mail to privacy@jdsupra.com. We will be in contact with you (by mail or otherwise) to verify your identity and provide you the information you request. We will respond within 30 days to your request for access to your personal information. In some cases, we may not be able to remove your personal information, in which case we will let you know if we are unable to do so and why. If you would like to correct or update your personal information, you can manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard. If you would like to delete your account or remove your information from our Website and Services, send an e-mail to privacy@jdsupra.com.

Changes in Our Privacy Policy

We reserve the right to change this Privacy Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our Privacy Policy will become effective upon posting of the revised policy on the Website. By continuing to use our Website and Services following such changes, you will be deemed to have agreed to such changes.

Contacting JD Supra

If you have any questions about this Privacy Policy, the practices of this site, your dealings with our Website or Services, or if you would like to change any of the information you have provided to us, please contact us at: privacy@jdsupra.com.

JD Supra Cookie Guide

As with many websites, JD Supra's website (located at www.jdsupra.com) (our "Website") and our services (such as our email article digests)(our "Services") use a standard technology called a "cookie" and other similar technologies (such as, pixels and web beacons), which are small data files that are transferred to your computer when you use our Website and Services. These technologies automatically identify your browser whenever you interact with our Website and Services.

How We Use Cookies and Other Tracking Technologies

We use cookies and other tracking technologies to:

  1. Improve the user experience on our Website and Services;
  2. Store the authorization token that users receive when they login to the private areas of our Website. This token is specific to a user's login session and requires a valid username and password to obtain. It is required to access the user's profile information, subscriptions, and analytics;
  3. Track anonymous site usage; and
  4. Permit connectivity with social media networks to permit content sharing.

There are different types of cookies and other technologies used our Website, notably:

  • "Session cookies" - These cookies only last as long as your online session, and disappear from your computer or device when you close your browser (like Internet Explorer, Google Chrome or Safari).
  • "Persistent cookies" - These cookies stay on your computer or device after your browser has been closed and last for a time specified in the cookie. We use persistent cookies when we need to know who you are for more than one browsing session. For example, we use them to remember your preferences for the next time you visit.
  • "Web Beacons/Pixels" - Some of our web pages and emails may also contain small electronic images known as web beacons, clear GIFs or single-pixel GIFs. These images are placed on a web page or email and typically work in conjunction with cookies to collect data. We use these images to identify our users and user behavior, such as counting the number of users who have visited a web page or acted upon one of our email digests.

JD Supra Cookies. We place our own cookies on your computer to track certain information about you while you are using our Website and Services. For example, we place a session cookie on your computer each time you visit our Website. We use these cookies to allow you to log-in to your subscriber account. In addition, through these cookies we are able to collect information about how you use the Website, including what browser you may be using, your IP address, and the URL address you came from upon visiting our Website and the URL you next visit (even if those URLs are not on our Website). We also utilize email web beacons to monitor whether our emails are being delivered and read. We also use these tools to help deliver reader analytics to our authors to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

Analytics/Performance Cookies. JD Supra also uses the following analytic tools to help us analyze the performance of our Website and Services as well as how visitors use our Website and Services:

  • HubSpot - For more information about HubSpot cookies, please visit legal.hubspot.com/privacy-policy.
  • New Relic - For more information on New Relic cookies, please visit www.newrelic.com/privacy.
  • Google Analytics - For more information on Google Analytics cookies, visit www.google.com/policies. To opt-out of being tracked by Google Analytics across all websites visit http://tools.google.com/dlpage/gaoptout. This will allow you to download and install a Google Analytics cookie-free web browser.

Facebook, Twitter and other Social Network Cookies. Our content pages allow you to share content appearing on our Website and Services to your social media accounts through the "Like," "Tweet," or similar buttons displayed on such pages. To accomplish this Service, we embed code that such third party social networks provide and that we do not control. These buttons know that you are logged in to your social network account and therefore such social networks could also know that you are viewing the JD Supra Website.

Controlling and Deleting Cookies

If you would like to change how a browser uses cookies, including blocking or deleting cookies from the JD Supra Website and Services you can do so by changing the settings in your web browser. To control cookies, most browsers allow you to either accept or reject all cookies, only accept certain types of cookies, or prompt you every time a site wishes to save a cookie. It's also easy to delete cookies that are already saved on your device by a browser.

The processes for controlling and deleting cookies vary depending on which browser you use. To find out how to do so with a particular browser, you can use your browser's "Help" function or alternatively, you can visit http://www.aboutcookies.org which explains, step-by-step, how to control and delete cookies in most browsers.

Updates to This Policy

We may update this cookie policy and our Privacy Policy from time-to-time, particularly as technology changes. You can always check this page for the latest version. We may also notify you of changes to our privacy policy by email.

Contacting JD Supra

If you have any questions about how we use cookies and other tracking technologies, please contact us at: privacy@jdsupra.com.

- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.